Increased Infection Risk in Addison’s Disease and Congenital Adrenal Hyperplasia

Context Mortality and infection-related hospital admissions are increased in patients with primary adrenal insufficiency (PAI). However, the risk of primary care-managed infections in patients with PAI is unknown. Objective To estimate infection risk in PAI due to Addison’s disease (AD) and congenital adrenal hyperplasia (CAH) in a primary care setting. Design Retrospective cohort study using UK data collected from 1995 to 2018. Main outcome measures Incidence of lower respiratory tract infections (LRTIs), urinary tract infections (UTIs), gastrointestinal infections (GIIs), and prescription counts of antimicrobials in adult PAI patients compared to unexposed controls. Results A diagnosis of PAI was established in 1580 AD patients (mean age 51.7 years) and 602 CAH patients (mean age 35.4 years). All AD patients and 42% of CAH patients were prescribed glucocorticoids, most frequently hydrocortisone in AD (82%) and prednisolone in CAH (50%). AD and CAH patients exposed to glucocorticoids, but not CAH patients without glucocorticoid treatment, had a significantly increased risk of LRTIs (adjusted incidence rate ratio AD 2.11 [95% confidence interval 1.64-2.69], CAH 3.23 [1.21-8.61]), UTIs (AD 1.51 [1.29-1.77], CAH 2.20 [1.43-3.34]), and GIIs (AD 3.80 [2.99-4.84], CAH 1.93 [1.06-3.52]). This was mirrored by increased prescription of antibiotics (AD 1.73 [1.69-1.77], CAH 1.77 [1.66-1.89]) and antifungals (AD 1.89 [1.74-2.05], CAH 1.91 [1.50-2.43]). Conclusions There is an increased risk of infections and antimicrobial use in PAI in the primary care setting at least partially linked to glucocorticoid treatment. Future studies will need to address whether more physiological glucocorticoid replacement modes could reduce this risk. Précis Using data from 1580 AD patients and 602 CAH patients collected in a UK primary care database from 1995 to 2018, we identified increased risk of infections and antimicrobial prescription counts.

[1]  R. Murray,et al.  Glucocorticoid management of adrenal insufficiency in the United Kingdom: assessment using real-world data , 2018, Endocrine connections.

[2]  A. Mallappa,et al.  Long‐term use of continuous subcutaneous hydrocortisone infusion therapy in patients with congenital adrenal hyperplasia , 2018, Clinical endocrinology.

[3]  C. Currie,et al.  Poor compliance and increased mortality, depression and healthcare costs in patients with congenital adrenal hyperplasia. , 2018, European journal of endocrinology.

[4]  M. Quinkler,et al.  Adrenal disease: Imitating the cortisol profile improves the immune system , 2018, Nature Reviews Endocrinology.

[5]  D. Farewell,et al.  Incidence and antibiotic prescribing for clinically diagnosed urinary tract infection in older adults in UK primary care, 2004-2014 , 2018, PloS one.

[6]  P. Pasqualetti,et al.  Effect of once-daily, modified-release hydrocortisone versus standard glucocorticoid therapy on metabolism and innate immunity in patients with adrenal insufficiency (DREAM): a single-blind, randomised controlled trial. , 2017, The lancet. Diabetes & endocrinology.

[7]  R. Murray,et al.  Management of glucocorticoid replacement in adrenal insufficiency shows notable heterogeneity – data from the EU‐AIR , 2017, Clinical endocrinology.

[8]  J. Lord,et al.  Primary adrenal insufficiency is associated with impaired natural killer cell function: a potential link to increased mortality , 2017, European journal of endocrinology.

[9]  I. Petersen,et al.  Common Infections in Patients Prescribed Systemic Glucocorticoids in Primary Care: A Population-Based Cohort Study , 2016, PLoS medicine.

[10]  J. West,et al.  A comparison of the recording of comorbidity in primary and secondary care by using the Charlson Index to predict short-term and long-term survival in a routine linked data cohort , 2015, BMJ Open.

[11]  T. Jorgensen,et al.  Suppressive effects of androgens on the immune system. , 2015, Cellular immunology.

[12]  S. Hahner,et al.  Diagnosis and management of adrenal insufficiency. , 2015, The lancet. Diabetes & endocrinology.

[13]  M. Polak,et al.  Inadequate Cortisol Response to the Tetracosactide (Synacthen®) Test in Non-Classic Congenital Adrenal Hyperplasia: An Exception to the Rule? , 2015, Hormone Research in Paediatrics.

[14]  H. Falhammar,et al.  Increased mortality in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. , 2014, The Journal of clinical endocrinology and metabolism.

[15]  D. Torpy,et al.  Continuous subcutaneous hydrocortisone infusion therapy in Addison's disease: a randomized, placebo-controlled clinical trial. , 2014, The Journal of clinical endocrinology and metabolism.

[16]  M. Debono,et al.  An oral multiparticulate, modified‐release, hydrocortisone replacement therapy that provides physiological cortisol exposure , 2014, Clinical endocrinology.

[17]  P. Souverein,et al.  Increased use of antimicrobial agents and hospital admission for infections in patients with primary adrenal insufficiency: a cohort study. , 2013, European journal of endocrinology.

[18]  J. Ludvigsson,et al.  Drug prescription patterns in patients with Addison's disease: a Swedish population-based cohort study. , 2013, The Journal of clinical endocrinology and metabolism.

[19]  C. Whitney,et al.  Use of 13‐Valent Pneumococcal Conjugate Vaccine and 23‐Valent Pneumococcal Polysaccharide Vaccine for Adults With Immunocompromising Conditions: Recommendations of the Advisory Committee on Immunization Practices (ACIP) , 2013, MMWR. Morbidity and mortality weekly report.

[20]  S. Skrtic,et al.  Current practice of glucocorticoid replacement therapy and patient-perceived health outcomes in adrenal insufficiency - a worldwide patient survey , 2012, BMC Endocrine Disorders.

[21]  A. Bourke,et al.  Generalisability of The Health Improvement Network (THIN) database: demographics, chronic disease prevalence and mortality rates. , 2011, Informatics in primary care.

[22]  J. Connell,et al.  Health Status of Adults with Congenital Adrenal Hyperplasia: A Cohort Study of 203 Patients , 2010, The Journal of clinical endocrinology and metabolism.

[23]  A. Maguire,et al.  The importance of defining periods of complete mortality reporting for research using automated data from primary care , 2009, Pharmacoepidemiology and drug safety.

[24]  J. Svartberg,et al.  Normal overall mortality rate in Addison's disease, but young patients are at risk of premature death. , 2008, European journal of endocrinology.

[25]  W. Bilker,et al.  Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research , 2007, Pharmacoepidemiology and drug safety.

[26]  G. Johannsson,et al.  Premature mortality in patients with Addison's disease: a population-based study. , 2006, The Journal of clinical endocrinology and metabolism.

[27]  M. Rovers,et al.  Incidence of GP-diagnosed respiratory tract infections according to age, gender and high-risk co-morbidity: the Second Dutch National Survey of General Practice. , 2006, Family practice.

[28]  K. W. Cross,et al.  Recent changes in the prevalence of diseases presenting for health care. , 2005, The British journal of general practice : the journal of the Royal College of General Practitioners.

[29]  F. Mantero,et al.  Autoimmune adrenal insufficiency and autoimmune polyendocrine syndromes: autoantibodies, autoantigens, and their applicability in diagnosis and disease prediction. , 2002, Endocrine reviews.

[30]  A. Bellastella,et al.  Immunological pattern in patients with 21-hydroxylase deficiency , 1994, Journal of endocrinological investigation.

[31]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.